IP Library Granted Patent US 10,456,468
Granted Patent B2
US 10,456,468 · App. 15/121,372 · Granted Oct 29, 2019

Fractionated radiotherapy and chemotherapy with an oxygen therapeutic

Inventor: Evan C. Unger (Tucson, AZ)
Assignee: NuvOx Pharma LLC
A61K41/0038A61K9/0019A61K9/107A61K31/02A61K33/00A61K39/395A61K45/06A61K47/10A61K47/24A61K47/26A61N5/10A61K2039/505A61K2039/545A61N2005/1098
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,456,468
App. No.
15/121,372
Granted
Oct 29, 2019
Kind
B2
Abstract

A fluorocarbon emulsion in water for use in fractionated radiotherapy and chemotherapy, wherein said fluorocarbon comprises between 4 and 8 carbon atoms.

Claims (13)

1. A method of sensitizing a mammal to multi-fraction radiotherapy or chemotherapy, comprising

concomitantly or up to 120 minutes prior to each fraction of radiation therapy or concomitantly with chemotherapy, administering a water emulsion of perfluoropentane to the mammal, wherein the perfluoropentane emulsion comprises a phospholipid, a viscosity modifier, a fluorosurfactant, and about 1% to 5% w/vol of perfluoropentane; and

simultaneously administering to said mammal carbogen or supplemental oxygen,

wherein the perfluoropentane emulsion is administered at a dosage in the range from about 0.05 cc/kg to about 0.3 cc/kg.

2. The method of claim 1 , wherein the perfluoropentane emulsion comprises about 2% w/vol of perfluoropentane.

3. The method of claim 1 , wherein administration of the perfluoropentane emulsion is intravenous infusion for up to 30 minutes.

4. The method of claim 1 , wherein administration of the perfluoropentane emulsion is intravenous infusion as a single bolus.

5. The method of claim 1 , wherein the fluorosurfactant is PEG Telomer B.

6. The method of claim 5 , wherein said viscosity modifier comprises sucrose.

7. The method of claim 6 , wherein said sucrose is present at about 300 mg/mL.

8. The method of claim 5 , wherein said fluorosurfactant is PEG Telomer B is present at about 3 mg/mL.

9. The method of claim 1 , wherein the perfluoropentane emulsion is co-administered with an anticancer agent.

10. The method of claim 9 , wherein said anticancer agent is an antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2026
From: UNGER, EVAN C, DR.
To: NUVOX PHARMA LLC
Reel/Frame 073808/0979 →
Continuity (2)
Provisional Application 61948406 · Mar 5, 2014
Related Publication 20160367670A1 · Dec 22, 2016
Cited By (3)
US 50,811 US 12,245,355 US 12,569,700